Potent inhibitor of ligand binding to the integrins alpha-V/beta-3 (ITGAV/ITGB3) (IC(50)=20.7 nM), alpha-IIb/beta-3 (ITGA2B/ITGB3) (IC(50)=51.5 nM), alpha-5/beta-1 (ITGA5/ITGB1) (IC(50)=132.6 nM), and moderate inhibitor of ligand binding to the integrin alpha-V/beta-5 (ITGAV/ITGB5) (IC(50)=286.4 nM). Competition with fibrinogen for the RGD recognition sites on the alpha-IIb/beta-3 integrin (glyco-protein IIb/IIIa complex) results in the inhibition of platelet aggregation and other antithrombotic properties such as an ability to prevent coronary thrombosis in animal models (Probable). Is also a potent inhibitor of bone resorption. This results from the blocking of the interaction of alpha-V/beta-3 integrin on the surface of osteoclasts with bone extracellular matrix (Probable). In addition, interaction with alpha-V/beta-3 also inhibits human umbilical vein endothelial cells (HUVEC) proliferation (IC(50)=103.2 nM) and inhibits the migration of some tumor cells (IC(50)=1.5-154.5 nM), suggesting that this disintegrin could be a good scaffold to design potent antiangiogenic agents by modifying its unique C-terminal tail structure (Probable)